Biotech Opportunities Today: Intuitive Surgical (ISRG), Exelixis (EXEL), Gilead Sciences (GILD), Thoratec Corporation (THOR)

Intuitive Surgical Surges On Strong Earnings

Intuitive Surgical, Inc. (NASDAQ: ISRG)

Intuitive Surgical shares are soaring today after the company released its earnings report for the second quarter. In the report, investors saw that ISRG generated earnings per share of $.380; far outweighing the analyst expectations of $3.27 per share. When it comes to top-line revenue, the company blew expectations away there as well; generating $586 million in the quarter compared to the $568 million that was expected. That equates to year over year growth of 16%. All in all, investors were incredibly happy with the earnings report; sending the stock on a surge. Currently (12:25), ISRG is trading at $556.41 per share after a gain of 10.16% so far today. Given the reason for the climb, I’d expect to see more upward momentum. While we are likely to see a dip tomorrow, I wouldn’t be concerned about the decline as it is likely to represent a strong buying opportunity.

Exelixis Stock Continues To Climb On Phase 3 Trial Data

Exelixis, Inc. (NASDAQ: EXEL)

Exelixis is making good on promises that I made yesterday. After a massive climb on Monday following a Phase 3 data release, we saw a bit of a correction. However, I published a post explaining why I wasn’t concerned about the declines. Ultimately, my prediction that we would see more gains today is coming to fruition. The bottom line is that the data associated with the study of cabozantinib was overwhelmingly positive; and is highly likely to lead to FDA approval and incredible profits down the road. With that said, I have an overwhelmingly bullish opinion of EXEL both short and long term. So, if you’re not already in, you may want to consider looking for pull backs as opportunities for an entrance. Currently (12:34), EXEL is trading at $6.15 per share after a gain of 1.65% so far today.

Gilead Sciences: Yet Another Reason The Discount Won’t Last Long

Gilead Sciences, Inc. (NASDAQ: GILD)

Today, Gilead Sciences announced data from a 48 week study evaluating a switch from TDF-based regimens to TAF0based regimens. The data released showed statistical superiority; giving investors yet another reason to be excited about the stock. In a statement, Tony Mills, MD, the lead author of the Phase 3 study had the following to say…

The results of the study demonstrate that E/C/F/TAF has the potential to offer clear advantages for patients with HIV over existing TDF-based therapies… This is the first large study to demonstrate that switching from a TDF-based regimen to E/C/F/TAF can help improve patients’ bone and kidney measures.”

This data comes just a short time before Gilead Sciences is set to release their earnings report for the second quarter; an event that I believe will prove to be a major catalyst for the company. Nonetheless, the stock is still trading at a heavy discount; giving profit seekers a strong opportunity to get in on the gains! So, if you’re not in already, it’s time to strongly consider GILD!

Thoratec Corporation Stock Is Up On St. Jude Takeover Offer

Thoratec Corporation (NASDAQ: THOR)

Thoratec Corporation stock is up today after St. Jude offered to acquire the company. The offer came in at $62.56 per share; representing a 10% premium over Tuesday’s closing price. According to the agreement, Thoratec corporation has until August 20th to look for other takeover offers. If the company is able to find a better deal before the deadline, St. Jude will have to pay a $30 million breakup fee. In a statement following the announcement Keith Grossman, THOR CEO had the following to say…

By combining the capabilities and leading technologies of both companies, we will be able to expand access, reduce costs and advance heart failure therapies on a global basis.”

All in all, investors seem happy with the offer as they push the stock’s value up. Currently (12:46), THOR is trading at $63.41 per share after a gain of 10.13% so far today.

Image Credit

Leave a Comment